Log in
OTCMKTS:NGENF

NervGen Pharma Stock Forecast, Price & News

$1.36
-0.04 (-2.52 %)
(As of 12/2/2020 02:39 PM ET)
Add
Compare
Today's Range
$1.34
Now: $1.36
$1.39
50-Day Range
$1.07
MA: $1.31
$1.45
52-Week Range
$0.55
Now: $1.36
$2.49
Volume18,220 shs
Average Volume24,617 shs
Market Capitalization$83.70 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NervGen Pharma Corp., a biotech company, discovers and develops treatments for patients suffering from medical conditions related to nerve damage. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NGENF
CUSIPN/A
CIKN/A
Phone902-442-4655
Employees7

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00

Profitability

Net Income$-4,070,000.00

Miscellaneous

Market Cap$83.70 million
Next Earnings DateN/A
OptionableNot Optionable
$1.36
-0.04 (-2.52 %)
(As of 12/2/2020 02:39 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NGENF News and Ratings via Email

Sign-up to receive the latest news and ratings for NGENF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NervGen Pharma (OTCMKTS:NGENF) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of NervGen Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NervGen Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for NervGen Pharma
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than NervGen Pharma?

Wall Street analysts have given NervGen Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NervGen Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for NGENF?

1 brokerages have issued 12-month price objectives for NervGen Pharma's shares. Their forecasts range from $4.00 to $4.00. On average, they expect NervGen Pharma's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 195.2% from the stock's current price.
View analysts' price targets for NervGen Pharma
.

Are investors shorting NervGen Pharma?

NervGen Pharma saw a drop in short interest during the month of October. As of October 30th, there was short interest totaling 2,000 shares, a drop of 59.2% from the October 15th total of 4,900 shares. Based on an average trading volume of 27,900 shares, the short-interest ratio is currently 0.1 days.
View NervGen Pharma's Short Interest
.

Who are some of NervGen Pharma's key competitors?

Who are NervGen Pharma's key executives?

NervGen Pharma's management team includes the following people:
  • Mr. William Joseph Radvak, Exec. Chairman (Age 57)
  • Mr. Paul Anthony Brennan B.Sc., M.Sc., Pres, CEO & Director
  • Dr. Ernest Shing-Yan Wong, Consultant & Advisor (Age 52)
  • Mr. Robert G. Pilz B.Com., C.P.A., BComm, CMA, Consultant (Age 54)
  • Mr. Brian McAlister, Co-Founder & Advisor
  • Mr. William J. Adams C.A., CPA, CPA, CA, CFO & Corp. Sec. (Age 58)

What is NervGen Pharma's stock symbol?

NervGen Pharma trades on the OTCMKTS under the ticker symbol "NGENF."

How do I buy shares of NervGen Pharma?

Shares of NGENF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NervGen Pharma's stock price today?

One share of NGENF stock can currently be purchased for approximately $1.36.

How big of a company is NervGen Pharma?

NervGen Pharma has a market capitalization of $83.70 million and generates $150,000.00 in revenue each year. NervGen Pharma employs 7 workers across the globe.

What is NervGen Pharma's official website?

The official website for NervGen Pharma is www.appilitherapeutics.com.

How can I contact NervGen Pharma?

NervGen Pharma's mailing address is 21-1344 SUMMER ST., HALIFAX A5, B3H 0A8. The company can be reached via phone at 902-442-4655.

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.